Abstract 14409: Residual Risk of Ischemic Stroke Despite Anticoagulation in Patients Hospitalized with Atrial Fibrillation: Insights from the Get With The Guidelines-Atrial Fibrillation Program
Abstract
Background: Oral anticoagulation (OAC) substantially reduces stroke risk in atrial fibrillation (AF), yet residual risk persists even among treated patients. Contemporary real-world data on this residual risk, its determinants, and longitudinal adherence to OAC are limited. Methods: We analyzed patients ≥65 years of age hospitalized with AF in the Get With The Guidelines-Atrial Fibrillation (GWTG-AFIB) registry, linked to Medicare claims (2017-2023), who were discharged on OAC. Patients with contraindications, without guideline indication or an alternate indication for OAC were excluded. Outcomes included ischemic stroke/systemic embolism (SE) and all-cause mortality through 3 years. Incident rates were calculated per 1000 person-years. Factors associated with stroke were assessed using cause-specific Cox models with LASSO-based variable selection. Post-discharge adherence was assessed using the proportion of days covered (PDC ≥80%) from Medicare Part D data. Results: Among 15,873 patients (mean (SD) age 76(8) years; 55.8% female), 405 (2.6%) experienced stroke/SE over 3 years (incidence 11.9 per 1000 person-years), while all-cause mortality was 28.7% (incidence 124 per 1000 person-years). Residual stroke risk increased significantly with age (>75 years: 15.7 vs 7.9 per 1000 person-years), prior stroke/TIA (23.0 vs 9.8), diabetes (15.4 vs 10.5), and GARFIELD (stroke and systemic embolism) score >2 (25.0 vs 8.9) (all p<0.001) [Table 1]. Independent predictors of stroke included age (aHR:1.22 [1.14-1.30] per 5 years), prior stroke/TIA (aHR: 1.67[1.22, 2.27]), diabetes (aHR 1.48 [1.20, 1.84]), and GARFIELD risk >2 (aHR 1.52[1.11, 2.09]). OAC adherence remained 50-55% across all 6-month intervals through 3 years, with only ~40% of patients remaining under observation at 30-36 months [Figure 1]. Conclusions: Among patients hospitalized with AF and discharged on OAC, substantial residual stroke risk persists, driven by clinical risk factors rather than treatment gaps alone. Despite guideline-directed therapy being prescribed at discharge, long-term adherence remains suboptimal. These findings highlight the need for improved risk stratification and strategies to optimize sustained anticoagulation and adjunctive therapies.